2026 Q2 -tulosraportti
21 päivää sitten
‧48 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·27 min sittenAksjestrategi.no – builds the portfolio on insider deals The two latest stocks included in Aksjestrategi.no's insider portfolio are Borr Drilling (BORR) and Photocure (PHO). Both are chosen after registered insider activity – meaning that persons with close ties to the companies have traded shares. The idea behind the strategy is simple: Follow the money of those who know the company best. 📈 BORR – Borr Drilling: 41,85 kr, +9,1 %. Ranked as no. 5 out of 56 in our model, with score 118. 📈 PHO – Photocure: 54,40 kr, +5,6 %. Ranked as no. 12 out of 56, with score 78. This is not random stock picking. Aksjestrategi.no follows insider trades on Oslo Børs and uses them as an important signal in the hunt for interesting investments.
·2 päivää sittenhttps://www.finansavisen.no/finans/2026/08/14/8372937/to-innsidere-kjoper-tungt-vi-tar-inn-aksjen Two insiders buy heavily – we are adding the stock The Insider Portfolio was thoroughly beaten by Oslo Børs this week. Now we are making a new move and betting on Photocure after two significant insider purchases. Adding Photocure It is, however, far more interesting that two insider purchases have been made in Photocure for over 1 million kroner. The two purchases were made by chairman Dylan Hallerberg and board member Neal Shore. Especially the latter is significantly increasing his holdings, so Photocure is being added to the Insider Portfolio.- ·2 päivää sittenhttps://www.finansavisen.no/tdn/2026/08/17/06588431/photocure-fda-foreslar-a-endre-blc-systemer-fra-klasse-iii-til-klasse-ii PHOTOCURE: FDA PROPOSES TO CHANGE BLC SYSTEMS FROM CLASS III TO CLASS II Oslo (Infront TDN Direkt): The US Food and Drug Administration (FDA) has published a proposal to initiate the process of reclassifying cystoscopy systems for bladder cancer detection from Class III to Class II. This is stated in a release from Photocure on Friday. A final reclassification will entail a transition from the current PMA approval to a 510(k) pathway with special control requirements. Photocure believes this could facilitate more BLC-compatible systems and increased availability of Cysview in the USA. "This is a very important regulatory milestone for Photocure, doctors, and the bladder cancer community. The fact that the FDA has initiated the reclassification process on its own initiative reflects the agency's conclusion that sufficient information exists to establish special control requirements for these products, and at the same time provides important regulatory recognition of the documented safety and efficacy of BLC. We believe the proposed framework is much better adapted to the technology's long-standing clinical use and regulatory experience, and will be a significant catalyst for the business in the USA," says CEO Dan Schneider of Photocure. The proposal is still subject to public hearing and final consideration by the FDA.
·15.8.Is there anyone who can explain in a simple way, in plain language, what effect this will have for PHO if this reclassification is approved?
What does that mean in practice? 1. Lower regulatory barriers It becomes easier for equipment manufacturers to launch compatible BLC systems in the USA. This can reduce time and costs for new products. 1 2. More hospitals can adopt the technology Photocure believes that more equipment platforms will make it easier for hospitals and urologists to introduce BLC with Cysview into clinical practice. Increased access can lead to more examinations where Cysview is used. 1 3. Potentially higher sales of Cysview Photocure primarily earns money from the drug Cysview, which is used together with the blue light systems. If more compatible systems come onto the market, the number of procedures can increase and thereby also the demand for Cysview. 1 4. FDA recognizes the maturity of the technology FDA writes that there is sufficient scientific, clinical, and post-market data to establish special controls and maintain safety and effectiveness. This can be perceived as a regulatory quality stamp for the technology. 1 Are there any disadvantages? Yes. In the longer term, lower barriers can: make it easier for more players to enter the market, increase competition on the equipment side, reduce Photocure's exclusivity around the BLC ecosystem. But the market normally views this news as net positive, since Photocure's biggest challenge has long been to achieve wider adoption of the technology. More installed systems can lead to more Cysview treatments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
21 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·27 min sittenAksjestrategi.no – builds the portfolio on insider deals The two latest stocks included in Aksjestrategi.no's insider portfolio are Borr Drilling (BORR) and Photocure (PHO). Both are chosen after registered insider activity – meaning that persons with close ties to the companies have traded shares. The idea behind the strategy is simple: Follow the money of those who know the company best. 📈 BORR – Borr Drilling: 41,85 kr, +9,1 %. Ranked as no. 5 out of 56 in our model, with score 118. 📈 PHO – Photocure: 54,40 kr, +5,6 %. Ranked as no. 12 out of 56, with score 78. This is not random stock picking. Aksjestrategi.no follows insider trades on Oslo Børs and uses them as an important signal in the hunt for interesting investments.
- ·2 päivää sittenhttps://www.finansavisen.no/finans/2026/08/14/8372937/to-innsidere-kjoper-tungt-vi-tar-inn-aksjen Two insiders buy heavily – we are adding the stock The Insider Portfolio was thoroughly beaten by Oslo Børs this week. Now we are making a new move and betting on Photocure after two significant insider purchases. Adding Photocure It is, however, far more interesting that two insider purchases have been made in Photocure for over 1 million kroner. The two purchases were made by chairman Dylan Hallerberg and board member Neal Shore. Especially the latter is significantly increasing his holdings, so Photocure is being added to the Insider Portfolio.
- ·2 päivää sittenhttps://www.finansavisen.no/tdn/2026/08/17/06588431/photocure-fda-foreslar-a-endre-blc-systemer-fra-klasse-iii-til-klasse-ii PHOTOCURE: FDA PROPOSES TO CHANGE BLC SYSTEMS FROM CLASS III TO CLASS II Oslo (Infront TDN Direkt): The US Food and Drug Administration (FDA) has published a proposal to initiate the process of reclassifying cystoscopy systems for bladder cancer detection from Class III to Class II. This is stated in a release from Photocure on Friday. A final reclassification will entail a transition from the current PMA approval to a 510(k) pathway with special control requirements. Photocure believes this could facilitate more BLC-compatible systems and increased availability of Cysview in the USA. "This is a very important regulatory milestone for Photocure, doctors, and the bladder cancer community. The fact that the FDA has initiated the reclassification process on its own initiative reflects the agency's conclusion that sufficient information exists to establish special control requirements for these products, and at the same time provides important regulatory recognition of the documented safety and efficacy of BLC. We believe the proposed framework is much better adapted to the technology's long-standing clinical use and regulatory experience, and will be a significant catalyst for the business in the USA," says CEO Dan Schneider of Photocure. The proposal is still subject to public hearing and final consideration by the FDA.
- ·15.8.Is there anyone who can explain in a simple way, in plain language, what effect this will have for PHO if this reclassification is approved?What does that mean in practice? 1. Lower regulatory barriers It becomes easier for equipment manufacturers to launch compatible BLC systems in the USA. This can reduce time and costs for new products. 1 2. More hospitals can adopt the technology Photocure believes that more equipment platforms will make it easier for hospitals and urologists to introduce BLC with Cysview into clinical practice. Increased access can lead to more examinations where Cysview is used. 1 3. Potentially higher sales of Cysview Photocure primarily earns money from the drug Cysview, which is used together with the blue light systems. If more compatible systems come onto the market, the number of procedures can increase and thereby also the demand for Cysview. 1 4. FDA recognizes the maturity of the technology FDA writes that there is sufficient scientific, clinical, and post-market data to establish special controls and maintain safety and effectiveness. This can be perceived as a regulatory quality stamp for the technology. 1 Are there any disadvantages? Yes. In the longer term, lower barriers can: make it easier for more players to enter the market, increase competition on the equipment side, reduce Photocure's exclusivity around the BLC ecosystem. But the market normally views this news as net positive, since Photocure's biggest challenge has long been to achieve wider adoption of the technology. More installed systems can lead to more Cysview treatments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
2026 Q2 -tulosraportti
21 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·27 min sittenAksjestrategi.no – builds the portfolio on insider deals The two latest stocks included in Aksjestrategi.no's insider portfolio are Borr Drilling (BORR) and Photocure (PHO). Both are chosen after registered insider activity – meaning that persons with close ties to the companies have traded shares. The idea behind the strategy is simple: Follow the money of those who know the company best. 📈 BORR – Borr Drilling: 41,85 kr, +9,1 %. Ranked as no. 5 out of 56 in our model, with score 118. 📈 PHO – Photocure: 54,40 kr, +5,6 %. Ranked as no. 12 out of 56, with score 78. This is not random stock picking. Aksjestrategi.no follows insider trades on Oslo Børs and uses them as an important signal in the hunt for interesting investments.
- ·2 päivää sittenhttps://www.finansavisen.no/finans/2026/08/14/8372937/to-innsidere-kjoper-tungt-vi-tar-inn-aksjen Two insiders buy heavily – we are adding the stock The Insider Portfolio was thoroughly beaten by Oslo Børs this week. Now we are making a new move and betting on Photocure after two significant insider purchases. Adding Photocure It is, however, far more interesting that two insider purchases have been made in Photocure for over 1 million kroner. The two purchases were made by chairman Dylan Hallerberg and board member Neal Shore. Especially the latter is significantly increasing his holdings, so Photocure is being added to the Insider Portfolio.
- ·2 päivää sittenhttps://www.finansavisen.no/tdn/2026/08/17/06588431/photocure-fda-foreslar-a-endre-blc-systemer-fra-klasse-iii-til-klasse-ii PHOTOCURE: FDA PROPOSES TO CHANGE BLC SYSTEMS FROM CLASS III TO CLASS II Oslo (Infront TDN Direkt): The US Food and Drug Administration (FDA) has published a proposal to initiate the process of reclassifying cystoscopy systems for bladder cancer detection from Class III to Class II. This is stated in a release from Photocure on Friday. A final reclassification will entail a transition from the current PMA approval to a 510(k) pathway with special control requirements. Photocure believes this could facilitate more BLC-compatible systems and increased availability of Cysview in the USA. "This is a very important regulatory milestone for Photocure, doctors, and the bladder cancer community. The fact that the FDA has initiated the reclassification process on its own initiative reflects the agency's conclusion that sufficient information exists to establish special control requirements for these products, and at the same time provides important regulatory recognition of the documented safety and efficacy of BLC. We believe the proposed framework is much better adapted to the technology's long-standing clinical use and regulatory experience, and will be a significant catalyst for the business in the USA," says CEO Dan Schneider of Photocure. The proposal is still subject to public hearing and final consideration by the FDA.
- ·15.8.Is there anyone who can explain in a simple way, in plain language, what effect this will have for PHO if this reclassification is approved?What does that mean in practice? 1. Lower regulatory barriers It becomes easier for equipment manufacturers to launch compatible BLC systems in the USA. This can reduce time and costs for new products. 1 2. More hospitals can adopt the technology Photocure believes that more equipment platforms will make it easier for hospitals and urologists to introduce BLC with Cysview into clinical practice. Increased access can lead to more examinations where Cysview is used. 1 3. Potentially higher sales of Cysview Photocure primarily earns money from the drug Cysview, which is used together with the blue light systems. If more compatible systems come onto the market, the number of procedures can increase and thereby also the demand for Cysview. 1 4. FDA recognizes the maturity of the technology FDA writes that there is sufficient scientific, clinical, and post-market data to establish special controls and maintain safety and effectiveness. This can be perceived as a regulatory quality stamp for the technology. 1 Are there any disadvantages? Yes. In the longer term, lower barriers can: make it easier for more players to enter the market, increase competition on the equipment side, reduce Photocure's exclusivity around the BLC ecosystem. But the market normally views this news as net positive, since Photocure's biggest challenge has long been to achieve wider adoption of the technology. More installed systems can lead to more Cysview treatments.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt